den Broeder A A, Joosten L A B, Saxne T, Heinegård D, Fenner H, Miltenburg A M M, Frasa W L H, van Tits L J, Buurman W A, van Riel P L C M, van de Putte L B A, Barrera P
Department of Rheumatology, University Medical Centre Nijmegen, The Netherlands.
Ann Rheum Dis. 2002 Apr;61(4):311-8. doi: 10.1136/ard.61.4.311.
To investigate the effect of prolonged neutralisation of tumour necrosis factor alpha (TNFalpha) on the radiological course in rheumatoid arthritis (RA). To assess whether the radiological course can be predicted by clinical variables or biological markers of cartilage and synovium turnover and of endothelial activation.
Forty seven patients with active RA enrolled at our centre in monotherapy trials with adalimumab (D2E7), a fully human anti-TNFalpha monoclonal antibody, were studied for two years. Radiographs of hands and feet obtained at baseline and after one and two years were scored in chronological order by a single, blinded observer using the modified Sharp method. Radiological course was classified as stable or progressive using the smallest detectable difference as cut off point. The relation between radiological course and serum markers of cartilage and synovium turnover (metalloproteinases (MMP-1 and MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein-39 (HC gp-39)), endothelial activation (soluble E-selectin and intercellular adhesion molecule (ICAM-1)), and integrated measures of disease activity were assessed using univariate and multivariate analysis.
Radiological evaluation was performed in 36 patients with paired sets of radiographs at baseline and two years. After two years a total of 15/36 (42%) presented no radiological progression. More patients with stable radiological course were still receiving anti-TNFalpha treatment after two years (13/15 (87%) v 11/21 (52%); p=0.03) and had lower baseline COMP and sICAM-1 levels (p=0.01 and 0.04, respectively) than those in the group with progressive disease. In a logistic regression model the combination of sustained TNF neutralisation and baseline COMP and sICAM-1 levels was predictive for radiological outcome (p=0.03). C reactive protein and disease activity score area under the curve were significantly correlated with changes in radiological scores after two years (r=0.40 and 0.37, p<0.05). Long term TNFalpha neutralisation decreased the levels of COMP, sICAM, MMPs, and HC gp-39, but not sE-selectin.
The results suggest that long term monotherapy with anti-TNFalpha has a positive effect on radiological outcome and modulates cartilage and synovium turnover as measured by biological markers. Baseline serum sICAM-1 levels and COMP levels may be helpful to identify patients with progressive or non-progressive radiological outcome.
研究长期中和肿瘤坏死因子α(TNFα)对类风湿关节炎(RA)放射学病程的影响。评估放射学病程是否可通过软骨和滑膜更新以及内皮细胞活化的临床变量或生物学标志物进行预测。
对在我们中心参加阿达木单抗(D2E7,一种全人源抗TNFα单克隆抗体)单药治疗试验的47例活动性RA患者进行了为期两年的研究。由一名单盲观察者使用改良Sharp方法按时间顺序对基线时以及1年和2年后获得的手和足的X线片进行评分。以最小可检测差异作为分界点,将放射学病程分为稳定或进展。使用单变量和多变量分析评估放射学病程与软骨和滑膜更新的血清标志物(金属蛋白酶(MMP-1和MMP-3)、软骨寡聚基质蛋白(COMP)、人软骨糖蛋白-39(HC gp-39))、内皮细胞活化(可溶性E-选择素和细胞间黏附分子(ICAM-1))以及疾病活动综合指标之间的关系。
对36例在基线和两年时有配对X线片的患者进行了放射学评估。两年后,共有15/36(42%)患者无放射学进展。放射学病程稳定的患者在两年后仍接受抗TNFα治疗的比例更高(13/15(87%)对11/21(52%);p = 0.03),且其基线COMP和sICAM-1水平低于疾病进展组患者(分别为p = 0.·01和0.04)。在逻辑回归模型中,持续的TNF中和与基线COMP和sICAM-1水平的组合可预测放射学结果(p = 0.03)。C反应蛋白和疾病活动评分曲线下面积与两年后的放射学评分变化显著相关(r = 0.40和0.37,p < 0.05)。长期TNFα中和降低了COMP、sICAM、MMPs和HC gp-39的水平,但未降低sE-选择素水平。
结果表明,抗TNFα长期单药治疗对放射学结果有积极影响,并可通过生物学标志物调节软骨和滑膜更新。基线血清sICAM-1水平和COMP水平可能有助于识别放射学结果为进展或非进展的患者。